Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateJun 3, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-k, disclosure, financials

TL;DR

Foghorn Therapeutics filed a routine 8-K with standard disclosures. No major news.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting of these items.

Why It Matters

This 8-K filing indicates that Foghorn Therapeutics is providing standard disclosures and financial information to the SEC, which is routine for public companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for Regulation FD Disclosure and Financial Statements and Exhibits, indicating no unusual or high-risk events.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • 0001822462 (company) — Central Index Key
  • 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
  • 001-39634 (company) — SEC File Number
  • June 3, 2024 (date) — Date of Report

FAQ

What is the primary purpose of this 8-K filing by Foghorn Therapeutics Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

On what date was this 8-K report filed?

The report was filed on June 3, 2024.

What is Foghorn Therapeutics Inc.'s state of incorporation?

Foghorn Therapeutics Inc. is incorporated in Delaware.

What is the Standard Industrial Classification code listed for Foghorn Therapeutics Inc.?

The Standard Industrial Classification code listed is 2834, which corresponds to Pharmaceutical Preparations.

What is the principal executive office address for Foghorn Therapeutics Inc.?

The address of the principal executive offices is 500 Technology Square, Suite 700, Cambridge, MA 02139.

Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-03 16:02:48

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation dated June 2024, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation dated June 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: June 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.